FDA responds to NDA for glaucoma drug

17:05 EDT 7 Aug 2017 | Healio

The FDA has sent a complete response letter to Valeant Pharmaceuticals regarding the new drug application for the Bausch + Lomb latanoprostene bunod ophthalmic solution 0.024% product called Vyzulta.The investigational single-agent IOP-lowering eye drop is intended for treatment of open angle glaucoma or ocular hypertension.

Original Article: FDA responds to NDA for glaucoma drug


More From BioPortfolio on "FDA responds to NDA for glaucoma drug"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...